wayground logo

Free Printable Worksheets

Font size

S
M
L
XL
Worksheets

NCM 106

Total questions: 58

Worksheet time: 37mins

Name
Class
Date
1.

official or non-proprietary name ; universally accepted

a)

Generic name

b)

Brand (trade) name

c)

Chemical name

2.

chemicals that are introduced into the body to cause some sort of change

(a)  

3.

study of substances that interact with the living systems through chemical processes, by binding to regulatory molecules & activating or inhibiting normal body processes

a)

Pharmacotherapeutics (Clinical Pharmacology)

b)

Pharmacology

c)

Drug study

d)

Pharmacist

4.

compilation of the package insert information from drugs used in this country, along with some drug advertising

a)

Drug labels

b)

Physician’s Drug Reference (PDR)

c)

Package insert

d)

Reference books

5.

available form (tablet/ capsule/ syrup/ suspension, etc.)

(a)  

6.

proprietary name ; registered trademark owned by that specific manufacturer that developed it

a)

Generic name

b)

Brand (trade) name

c)

Chemical name

7.

dose available in the product

(a)  

8.

chemicals that are produced by companies involved solely in the manufacturing of drugs

a)

Orphan drugs

b)

Generic drugs

c)

Over-the-counter (OTC) drugs

9.

specific batch from which the drug was produced; important for recall information

(a)  

10.

have specific information that identifies a specific drug

a)

Drug labels

b)

Physician’s Drug Reference (PDR)

c)

Package insert

d)

Reference books

11.

pharmaceutical company that produces the drug

(a)  

12.

for drug information

a)

Drug labels

b)

Physician’s Drug Reference (PDR)

c)

Package insert

d)

Reference books

13.

name that reflects the chemical structure of a drug

a)

Generic name

b)

Brand (trade) name

c)

Chemical name

14.

indicates date after which the drug should be used

(a)  

15.

drugs that have been discovered but are not financially viable and therefore have not been "adopted" by any drug company because they have limited market or a narrow margin of safety

a)

Orphan drugs

b)

Generic drugs

c)

Over-the-counter (OTC) drugs

16.

branch of pharmaceutical that uses drugs to treat, prevent, and diagnose disease ; addresses two key concerns: the drug's effects on the body, and the body's response to the drug

a)

Pharmacotherapeutics (Clinical Pharmacology)

b)

Pharmacology

c)

Drug study

d)

Pharmacist

17.

an agency responsible for the regulation and enforcement of drug evaluation and distribution policies

a)

DEA (Drug Inforcement Agency)

b)

PDEA (Philippine Drug Enforcement Agency)

c)

FDA (Food and Drug Administration)

d)

DDB (Dangerous Drugs Board)

18.

contains all of the chemical and study information that led to the drug's approval

a)

Drug labels

b)

Physician’s Drug Reference (PDR)

c)

Package insert

d)

Reference books

19.

drugs with abuse potential

(a)  

20.

products that are available without prescription for self-treatment of a variety of complaints

a)

Orphan drugs

b)

Generic drugs

c)

Over-the-counter (OTC) drugs

21.

used to treat cardiac disorders

a)

various opiates (poppy)

b)

digitalis (foxglove)

c)

dronabinol (marinol)

22.

substance made by chemical synthesis to imitate a natural product

(a)  

23.

used to replace human chemicals that fail to be produced because of disease or genetic problems

(a)  

24.

used for sedation are still derived from plants

a)

various opiates (poppy)

b)

digitalis (foxglove)

c)

dronabinol (marinol)

25.

growth hormone preparations ; obtained from animal thyroid and hypothalamic tissues.

(a)  

26.

various chemical elements can have therapeutic effects in the human body

(a)  

27.

contains the active ingredient delta-9-tetrahydrocannabinol found in marijuana ; helps to prevent nausea and vomiting in cancer patients

a)

various opiates (poppy)

b)

digitalis (foxglove)

c)

dronabinol (marinol)

28.

for treating diabetes ; obtained exclusively from the pancreas of cows and pigs.

(a)  

29.

used as medicines since prehistoric times

(a)  

30.

measure of the amount of drug necessary to produce an effect of a given magnitude

(a)  

31.

receptor in the cell nucleus ; activation through transcription

a)

kinase-linked

b)

ligand-gated ion channels

c)

G-protein coupled receptor

d)

Nuclear receptor

32.

narrow margin of safety

a)

Low Therapeutic Index

b)

High Therapeutic Index

33.

margin of safety ; the dose of the drug required to produce a desired effect to that which produces undesired effects

a)

Dose response

b)

Pharmacodynamics

c)

Therapeutic Index

34.

drug spans the cell membrane and opens the channel allowing ions to flow into and out of the cell (Na and Ca)

a)

kinase-linked

b)

ligand-gated ion channels

c)

G-protein coupled receptor

d)

Nuclear receptor

35.

as the concentration of a drug increases, its pharmacologic effect also gradually increases until all receptors are occupied and further increase in dose no further increase its effect

a)

Quantal dose response

b)

Graded dose response

36.

wide margin of safety

a)

Low Therapeutic Index

b)

High Therapeutic Index

37.

More severe than side effects and are always undesirable

a)

Side effects

b)

Toxic effects

c)

Adverse effects

38.

drugs bind onto a cell surface

a)

kinase-linked

b)

ligand-gated ion channels

c)

G-protein coupled receptor

d)

Nuclear receptor

39.

interactions between the chemical components of living systems and the foreign chemicals, including drugs, that enter those systems

a)

Dose response

b)

Pharmacodynamics

c)

Therapeutic Index

40.

mostly proteins ; drugs bind to receptors to activate or inhibit response

(a)  

41.

drug toxicity (dangerous) ; when the drug exceeds the therapeutic range or drug accumulation ; are not acceptable adverse effects but are potentially serious reactions to a drug

a)

Side effects

b)

Toxic effects

c)

Adverse effects

42.

certain pharmacological effects which can not be quantified but can only be said to be present or absent (all or none)

a)

Quantal dose response

b)

Graded dose response

43.

the relationship between the minimal vs. the maximal amount of drug dose needed to produce the desired drug response

a)

Dose response

b)

Pharmacodynamics

c)

Therapeutic Index

44.

ability of the drug to elicit a response when it interacts with a receptor

(a)  

45.

G-protein binds w/ GTP → enzyme or ion channel

a)

kinase-linked

b)

ligand-gated ion channels

c)

G-protein coupled receptor

d)

Nuclear receptor

46.

drugs that simulate or blocks the cholinergic receptors and affects all anatomic sites of location

a)

Non-specific drugs

b)

Antagonist

c)

Narrow therapeutic window

d)

Non-selective drugs

47.

are physiologic effects not related to desired drug effects (desirable/undesirable)

a)

Side effects

b)

Toxic effects

c)

Adverse effects

48.

more toxic

a)

Non-specific drugs

b)

Antagonist

c)

Narrow therapeutic window

d)

Wide therapeutic window

49.

the highest plasma concentration of drug at a specific time

a)

Peak Drug Level

b)

Therapeutic Range (Therapeutic Window)

c)

Loading Dose

50.

drugs that block a response

a)

Non-specific drugs

b)

Antagonist

c)

Narrow therapeutic window

d)

Agonist

51.

a large initial dose to achieve a rapid minimum effective concentration in the plasma

a)

Peak Drug Level

b)

Therapeutic Range (Therapeutic Window)

c)

Loading Dose

52.

drugs that produce a response

a)

Agonist

b)

Wide therapeutic window

c)

Non-selective drugs

d)

Antagonist

53.

occurs when the drug reaches its highest blood or plasma concentration

a)

Duration of Action

b)

Peak Action

c)

Onset of Action

54.

the length of time the drug has a pharmacologic effect

a)

Duration of Action

b)

Peak Action

c)

Onset of Action

55.

drugs acting on different receptors

a)

Agonist

b)

Wide therapeutic window

c)

Non-selective drugs

d)

Non-specific drugs

56.

less toxic

a)

Agonist

b)

Wide therapeutic window

c)

Non-selective drugs

d)

Narrow therapeutic window

57.

conc. of the drug in the plasma should be between the minimum effective concentration and the minimum toxic conc. (toxic effect)

a)

Peak Drug Level

b)

Therapeutic Range (Therapeutic Window)

c)

Loading Dose

58.

the time it takes to reach the minimum effective concentration (MEC) after the drug is administered

a)

Duration of Action

b)

Peak Action

c)

Onset of Action